Dr Reddy announces launch of Fulvestrant injection

Dr Reddy informed the bourses on Monday that it has launched Fulvestrant injection, 250 mg/5 ml (50 mg/ml) per single-dose syringe, a therapeutic equivalent generic version of Faslodex (fulvestrant) injection, 250 mg/5 ml (50 mg/ml), approved by United States Food & Drug Administration (USFDA).

As per IQVIA Health, the Faslodex brand and generic market had US sales of nearly US$ 407 million MAT for the twelve-month ended in June 2020.

The company in its exchange filing said that its Fulvestrant injection, 250 mg/5 ml (50 mg/ml) per single-dose syringe is available in a carton containing two 5 ml single-dose prefilled syringes.

With this, the company’s total product launch in the past one month is totalled to 5. Last week, the company had launched Methylphenidate Hydrochloride extended-release tablets USP, in the US market. Read here:
https://www.dsij.in/DSIJArticleDetail/ArtMID/10163/ArticleID/14717/Dr-Reddys-Laboratories-launches-generic-Concerta-in-US-market 

Meanwhile, the stock of Dr Reddy in today’s trading session opened on a positive note at Rs 4,460 apiece as against the previous close of Rs 4,422.25. The stock later surged to an intraday high of Rs 4,481. The stock has strongly recovered from its low hit in March and surged nearly 80 per cent from that level.